Natural Sugar Induction for Ranibizumab Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant humanized Ranibizumab using IPTG as an inducer face challenges such as high cost, metabolic burden on host cells, and potential regulatory concerns due to trace contaminations, which are not effectively addressed for cytoplasmic expression of antibody fragments.
Innovation Solution
A process employing natural sugars like lactose and galactose to induce the expression of light and heavy chains of recombinant humanized Ranibizumab, using a duet vector system for co-expression in E. coli BL21 (DE3) cells, followed by solubilization and refolding to produce biologically active forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If IPTG is used as an inducer for expression of rHu Ranibizumab, then expression induction is achieved, but metabolic burden on host cells increases and host cell damage occurs
Solution Approach 1:
The patent changes the chemical nature of the inducer from synthetic IPTG to natural sugars (lactose, galactose, or their mixture). This parameter change maintains the induction capability while eliminating the harmful metabolic burden on E. coli host cells, as natural sugars are innocuous to the host metabolism compared to IPTG
Solution Approach 2:
The patent replaces expensive synthetic IPTG with inexpensive natural sugars. Lactose and galactose are cheaper alternatives that achieve the same induction purpose without causing host cell damage, effectively a disposable, harm-free inducer system
2Productivity
If IPTG is used for induction, then expression is induced, but cost increases and trace contaminations occur causing regulatory concerns
Solution Approach 1:
The patent substitutes expensive IPTG with cheap natural sugars (lactose, galactose). These natural sugars eliminate trace contamination issues and regulatory concerns associated with synthetic inducers, while maintaining effective induction capability and reducing overall production cost
Solution Approach 2:
The patent converts the potential harm of synthetic inducer contamination into benefit by using natural sugars that are inherently safe and innocuous to the host system, thereby improving product purity and regulatory compliance while maintaining induction effectiveness
3Object-affected harmful factors
If natural sugars are used as inducers, then metabolic stress on bacterial cells is reduced and biomass increases, but induction effectiveness for antibody fragments may be insufficient
Solution Approach 1:
The patent merges two natural sugars (lactose and galactose) in a dual-sugar induction system. This combination leverages the metabolic benefits of natural sugars to reduce stress on bacterial cells while achieving effective induction of antibody fragment expression, overcoming the limitation of using single sugar inducers
Solution Approach 2:
The patent employs a composite induction system using both lactose and galactose together. This composite approach creates a synergistic effect that reduces metabolic stress on host cells while maintaining or enhancing induction effectiveness for complex antibody fragment expression compared to single sugar systems
Data Source
AI summary
The present invention provides an improved process for inducing the expression of the light chain and heavy chain of the said rHu biosimilar Ranibizumab by employing natural sugars such as lactose and galactose. The replacement of IPTG with natural sugars overcomes the regulatory limitation of synthetic element trace contamination in the final drug substance and reduces the burden on the recombinant host cell.